Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Chen, Qiang ^a,b   Xie, Long Xu ^c   Qing, Zhi Rong ^c   Li, Lie Jun ^c   Luo, Zhao Yun ^a   Lin, Min ^a   Zhang, Shi Ming ^d   Chen, Wen Zhou ^d   Lin, Bing Zhong ^e   Lin, Qi Li ^f   Li, Hui ^g   Chen, Wei Pian ^h   Zheng, Pei Yao ⁱ   Mao, Ling Zhi ^j   Chen, Chan Yu ^a   Yang, Chun ^a   Zhan, Yong Zhong ^a   Liu, Xiang Zhi ^a   Zheng, Jia Kun ^a   Yang, Li Ye ^a  

^a Chaozhou Central Hospital Affiliated to Southern Medical University   (China)

^b JILIN UNIVERSITY   (China)

^c Chaozhou Hybribio Limited Corporation   (China)

^d Chaozhou Health Bureau   (China)

^e Raoping County People's Hospital   (China)

^f Chaozhou People's Hospital   (China)

^g Chaozhou Gynecological and Pediatric Hospital   (China)

^h Chao'an County Gynecological and Pediatric Hospital   (China)

ⁱ Fengxi People's Hospital   (China)

^j GUANGDONG WOMEN AND CHILDREN HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; INCIDENCE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RURAL AREA; UTERINE CERVIX CANCER; CROSS-SECTIONAL STUDY; DNA SEQUENCE; GENETIC VARIABILITY; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; RURAL POPULATION; TREATMENT OUTCOME; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ADULT; CHINA; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; GENETIC VARIATION; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; REAL-TIME POLYMERASE CHAIN REACTION; RURAL POPULATION; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84863177597     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032149     Document Type: Article

References (31)

1. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
2. Trottier H, Burchell AN, (2009) Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 12: 291-307.
3. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2009) A review of human carcinogens-Part B: biological agents. Lancet Oncol 10: 321-322.
4. Yoshikawa H, (2009) Progress and challenges on HPV vaccination. Uirusu 59: 243-248.
5. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928-1943.
6. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa) 2: 868-878.
7. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, et al. (2009): Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373: 1949-1957.
8. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, et al. (2008) Health and economic outcomes of HPV 16, 18 vaccination in 72 GAVI-eligible countries. Vaccine 26: 4080-4093.
9. Herrero R, (2009) Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 199: 919-922.
10. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, et al. (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998.
11. Klintschar M, Neuhuber F, (2000) Evaluation of an alkaline lysis method for the extraction of DNA from whole blood and forensic stains for STR analysis. J Forensic Sci 45: 669-673.
12. Lin M, Yang LY, Li LJ, Wu JR, Peng YP, et al. (2008) Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust N Z J Obstet Gynaecol 48: 189-194.
13. (1989) The 1988 Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses. Developed and approved at a National Cancer Institute Workshop, Bethesda, Maryland, U.S.A., December 12-13, 1988. J Reprod Med 34: 779-785.
14. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, et al. (2010) Cervical Cancer Screening Group in China.Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 11: 1160-1171.
15. Li Q, Wu LN, Hu SY, Wu RF, Liu ZH, et al. (2009) Effect of HPV Multiplex PCR Fluorescence Test on Cervical Cancer Screening. Chinese Neoplasia 18: 315-318.
16. Cheng JY, Bian ML, Ma L, Chen Y, Liu J, (2010) Evaluation of real-time PCR for detection of high-risk human papillomavirus in cytological cervical samples. Chin J Clin Lab Sci 28: 113-114.
17. Jin Q, Shen K, Li H, Zhou XR, Huang HF, et al. (2009) Prevalence of human papillomavirus infection in women in Tibet Autonomous Region of China. Zhonghua Fu Chan Ke Za Zhi 44: 898-902.
18. Yip YC, Ngai KL, Vong HT, Tzang LC, Ji S, et al. (2010) Prevalence and genotype distribution of cervical human papillomavirus infection in Macao. J Med Virol 82: 1724-1729.
19. Li C, Wu M, Wang J, Zhang S, Zhu L, et al. (2010) A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing, People's Republic of China. Cancer Epidemiol Biomarkers Prev 19: 2655-2664.
20. Ye J, Cheng X, Chen X, Ye F, Lü W, et al. (2010) Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol J 7: 66.
21. Wu RF, Liu ZH, Zhou QZ, Wulan N, Wang Q, et al. (2010) Prevalence of high-risk human papillomavirus and incidence of cervical intraepithelial neoplasia in female populations in Shenzhen, Guangdong Province. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 32: 90-95.
22. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, et al. (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a metaanalysis. Lancet Infect Dis 7: 453-459.
23. Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, et al. (2006) Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer 95: 96-101.
24. Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, et al. (2006) Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer 95: 1593-1597.
25. Liu SS, Chan KY, Leung RC, Chan KK, Tam KF, et al. (2011) Prevalence and Risk Factors of Human Papillomavirus (HPV) Infection in Southern Chinese Women- A Population-Based Study. PLoS One 6 (5): e19244.
26. Inoue M, Sakaguchi J, Sasagawa T, Tango M, (2006) The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 16: 1007-1013.
27. Hildesheim A, Wang SS, (2002) Host and viral genetics and risk of cervical cancer: a review. Virus Res 89: 229-240.
28. Paolini F, Rollo F, Brandi R, Benevolo M, Mariani L, et al. (2011) High risk human papillomavirus genotyping in clinical samples: evaluation of different commercial tests. Int J Immunopathol Pharmacol 24: 127-138.
29. Liu SS, Leung RC, Chan KK, Cheung AN, Ngan HY, (2010) Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. J Clin Microbiol 48: 758-764.
30. Bosch FX, de Sanjose S, (2007) The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 23: 213-227.
31. Kjaer SK, Chackerian B, Brule van den AJ, Svare EI, Paull G, et al. (2001) High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 10: 101-106.